Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Influence of microRNA on drug resistant and sensitive multiple myeloma cells.
EF 2009-10
Résumé
Multiple Myeloma (MM) is an incurable B-cell neoplasia that has a prevalence of 65,000 patients in the North American continent with an estimated 3000 deaths per year. It is the second most common hematological malignancy, after non-Hodgkins Lymphoma. It is a clonal disorder characterized by the accumulation of malignant plasma cells, usually within the bone marrow. Myeloma cells have antiapoptotic signaling mechanisms which results in resistance to current chemotherapy treatments and ultimately a fatal outcome for most patients. Although the availability of new agents such as thalidomide, bortezomib and high dose therapies have led to improved responses and survival, individual patient survival is extremely variable and MM remains incurable. It is difficult to accurately predict prognostic outcomes and response to treatment with current testing. Over the past few years, microRNAs (miRNA) have been identified as an important new class of regulatory biomolecules. It has been suggested that alterations and over-expression of miRNA play a large role in most, if not all, human cancers. While some attempts have been made to use miRNA in classifying and staging MM, little is known about the expression of miRNA and the effect on response to treatment in MM. We have postulated that miRNA has an influence on drug resistance in multiple myeloma cells. Using whole genome analysis, we attempt to identify a genetic signature that identifies drug resistance to bortezomib. We will examine cells in vitro (in culture) and in vivo models (in mice) to determine the behavior of cells when we over-express or silence a gene. By gaining further understanding of the influence of miRNA on myeloma cells, it will be possible identify potential therapeutic targets. Based on the gene expression signatures, MM patients can be classified into more distinct groups for better treatments and therapies and increased survival rates.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
199715
Name
Stebner Erin M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Influence of microRNA on drug resistant and sensitive multiple myeloma cells.
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Gene Expression Profiling; In Vitro Studies; In Vivo Studies; Microarray; Microrna; Multiple Myeloma; Qrt-Pcr; Rna Extraction; Sirna; Tissue Collection
Abstract
Multiple Myeloma (MM) is an incurable B-cell neoplasia that has a prevalence of 65,000 patients in the North American continent with an estimated 3000 deaths per year. It is the second most common hematological malignancy, after non-Hodgkins Lymphoma. It is a clonal disorder characterized by the accumulation of malignant plasma cells, usually within the bone marrow. Myeloma cells have antiapoptotic signaling mechanisms which results in resistance to current chemotherapy treatments and ultimately a fatal outcome for most patients. Although the availability of new agents such as thalidomide, bortezomib and high dose therapies have led to improved responses and survival, individual patient survival is extremely variable and MM remains incurable. It is difficult to accurately predict prognostic outcomes and response to treatment with current testing. Over the past few years, microRNAs (miRNA) have been identified as an important new class of regulatory biomolecules. It has been suggested that alterations and over-expression of miRNA play a large role in most, if not all, human cancers. While some attempts have been made to use miRNA in classifying and staging MM, little is known about the expression of miRNA and the effect on response to treatment in MM. We have postulated that miRNA has an influence on drug resistance in multiple myeloma cells. Using whole genome analysis, we attempt to identify a genetic signature that identifies drug resistance to bortezomib. We will examine cells in vitro (in culture) and in vivo models (in mice) to determine the behavior of cells when we over-express or silence a gene. By gaining further understanding of the influence of miRNA on myeloma cells, it will be possible identify potential therapeutic targets. Based on the gene expression signatures, MM patients can be classified into more distinct groups for better treatments and therapies and increased survival rates.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stebner, Erin M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~